/ /

  • linkedin
  • Increase Font
  • Sharebar

    EMA committee recommends cenegermin for neurotrophic keratitis


    Decision pending

    If approved, Oxervate eye drops will be available at a dosage of 20 µg/ml. The drug has not yet been granted marketing authorisation in any country.

    The CHMP's recommendation will go to the European Commission for a decision on to grant European Union-wide marketing authorisation, while the Committee for Orphan Medicinal Products will determine whether to maintain orphan designation.

    Dompé is also exploring the use of cenergermin in other optic neuropathies, such as retinitis pigmentosa, glaucoma, dry eye syndrome, and retinitis pigmentosa.

    Meanwhile, researchers at Yamaguchi University and Hiroshima University are pursuing a similar approach to the treatment of neurotrophic keratitis using a combination of the neurotransmitter substance P and insulin-like growth factor 1 (IGF-1).

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results